title: Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
abstract: Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50 mg/m(2) thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX(L) was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX(L) and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA. ssayar@iupui.edu
authors.forename: Hamid
authors.initials: H
authors.lastname: Sayar
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Chan
authors.forename: Christie M
authors.initials: CM
authors.lastname: Orschell
authors.forename: Edward M
authors.initials: EM
authors.lastname: Chan
authors.forename: Zhangsheng
authors.initials: Z
authors.lastname: Yu
authors.forename: Daniel
authors.initials: D
authors.lastname: Hood
authors.forename: Artur
authors.initials: A
authors.lastname: Plett
authors.forename: Zhenyun
authors.initials: Z
authors.lastname: Yang
authors.forename: Chua Lin
authors.initials: CL
authors.lastname: Hui
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Nabinger
authors.forename: Kristopher J
authors.initials: KJ
authors.lastname: Kohlbacher
authors.forename: Evan S
authors.initials: ES
authors.lastname: West
authors.forename: Amanda
authors.initials: A
authors.lastname: Walter
authors.forename: Carol
authors.initials: C
authors.lastname: Sampson
authors.forename: Jingwei
authors.initials: J
authors.lastname: Wu
authors.forename: Larry D
authors.initials: LD
authors.lastname: Cripe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001374:Azacitidine / Q000627:therapeutic use*; D015672:Erythroid Precursor Cells / Q000187:drug effects*; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D051020:bcl-X Protein / Q000378:metabolism
chemical_list: D000964:Antimetabolites, Antineoplastic; C494811:BCL2L1 protein, human; D051020:bcl-X Protein; D004921:Erythropoietin; D001374:Azacitidine